Vimian Group AB
STO:VIMIAN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
24.7881
46.7
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Vimian Group AB
Accounts Payable
Vimian Group AB
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
V
|
Vimian Group AB
STO:VIMIAN
|
Accounts Payable
€23.7m
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
O
|
OssDsign AB
STO:OSSD
|
Accounts Payable
kr9.9m
|
CAGR 3-Years
52%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Accounts Payable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
D
|
Doxa AB
STO:DOXA
|
Accounts Payable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bactiguard Holding AB
STO:BACTI B
|
Accounts Payable
kr16.7m
|
CAGR 3-Years
24%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
||
S
|
S2Medical AB (publ)
STO:S2M
|
Accounts Payable
kr1.1m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
Vimian Group AB
Glance View
Vimian Group AB is a relatively new player making waves in the veterinary and animal health industries. Founded in Sweden, Vimian is structured as a conglomerate composed of specialized subsidiaries focused on different niche markets within veterinary services, diagnostics, and technology. This strategic structure enables the company to operate across various segments such as Veterinary Services, Specialty Pharma, MedTech, and Diagnostics, achieving a holistic approach to animal healthcare. By acquiring and partnering with innovative companies globally, Vimian capitalizes on synergies and cross-market opportunities, ensuring a competitive edge in each of its operational fields. The company’s diverse portfolio allows it to cater not only to pet owners and veterinary professionals but also to livestock industries, ensuring comprehensive coverage in the growing market of animal welfare and health. Vimian’s revenue streams are multi-faceted, generated from a blend of product sales, subscriptions, and service fees. For instance, within its Specialty Pharma segment, the company develops and sells pharmaceutical products designed to treat common and specialty conditions in animals, thus generating continuous revenue from veterinary practices worldwide. In the MedTech segment, Vimian offers cutting-edge medical devices and equipment, enhancing veterinary surgical and diagnostic capabilities, which drives sales. Meanwhile, their Diagnostics division provides innovative testing solutions that help veterinarians identify and treat animal diseases accurately, offering another lucrative revenue stream. This multi-pronged business model not only mitigates risk through diversification but also positions Vimian as a key player in meeting the rapidly evolving demands of animal health and care.
See Also
What is Vimian Group AB's Accounts Payable?
Accounts Payable
23.7m
EUR
Based on the financial report for Sep 30, 2024, Vimian Group AB's Accounts Payable amounts to 23.7m EUR.
What is Vimian Group AB's Accounts Payable growth rate?
Accounts Payable CAGR 3Y
37%
Over the last year, the Accounts Payable growth was -7%. The average annual Accounts Payable growth rates for Vimian Group AB have been 37% over the past three years .